EPHA2 and metastatic malignant neoplasm: After encouraging pre‐clinical data showing reduced tumor growth and increased taxane response after EphA2 depletion (Landen et al, 2005b; Shen et al, 2013; Petty et al, 2018), a clinical trial is testing direct EphA2 inhibition in advanced metastatic cancers (NCT01591356, https://clinicaltrials.gov).